Novo Nordisk's AI Ambitions Clash with a Deepening Financial Downturn

Novo Nordisk braces for a major 2026 profit drop amid US pricing pressure, while investing in AI drug discovery and restructuring its workforce. Key Q1 report due May 6.

Novo Nordisk shares, trading at €34.44, find themselves caught in a stark contradiction. While the Danish pharmaceutical giant unveils cutting-edge artificial intelligence to revolutionize drug discovery, it is simultaneously bracing for one of its most severe revenue declines in recent memory. This clash between technological promise and immediate financial pressure defines the tense atmosphere ahead of its quarterly report on May 6.

The company's financial guidance for 2026 casts a long shadow, forecasting a sales and adjusted profit drop of between five and 13 percent. This anticipated slump is driven by intense pricing pressure in the crucial US market, substantial discounts on weight-loss drugs, and looming patent expirations for key semaglutid-based products. The stock's performance reflects this anxiety, having shed almost 23 percent since the start of the year and sitting roughly 51 percent below its 52-week high of €70.13 reached in June 2025.

In a bid to navigate these headwinds, Novo Nordisk is undergoing a significant operational shift. After cutting approximately 7,800 positions last year, the company is now in a rebuilding phase, planning to hire around 2,000 new employees globally. About 1,400 of these roles have already been filled, with nearly 400 in Denmark alone. This hiring spree is a direct response to sustained high demand for its metabolic therapies, though it introduces its own challenges; the employee turnover rate is projected to rise to nearly 18 percent by the end of 2025.

Amidst this restructuring, the company is making a bold technological push. In collaboration with OpenAI, Novo Nordisk recently introduced "GPT-Rosalind," a specialized AI model for biology and translational medicine. The internally tested model reportedly outperformed 95 percent of human experts in predicting RNA sequences. With full integration targeted for the end of 2026, the ambition is to drastically shorten the traditional 10 to 15-year drug development timeline. Pilot programs are currently active across the entire value chain.

On the competitive front, rival Eli Lilly has encountered a setback. The US FDA has requested additional safety data for Lilly's drug "Foundayo," slowing its progress. Furthermore, Lilly's new oral weight-loss medication had a subdued launch, with only 1,390 prescriptions in its first week. Novo Nordisk may capitalize on this opening, especially as clinical data suggests its semaglutid therapy is better at preserving lean muscle mass than some rival treatments.

Recent clinical studies offer additional product-specific positives. An oral formulation of Wegovy demonstrated an average weight loss of 14 percent over 64 weeks, compared to 2.4 percent for a placebo. About 28 percent of participants on the 25-mg maintenance dose lost more than a fifth of their body weight. However, a separate AI analysis of over 400,000 social media reports on GLP-1 drugs, published in Nature in April 2026, highlighted that gastrointestinal issues remain the most common side effect at 37 percent, while also uncovering less-documented symptoms like menstrual cycle changes in nearly four percent of female users.

Technically, the stock appears oversold with a Relative Strength Index reading of 25. Management is supporting the share price through an ongoing buyback program worth 15 billion Danish kroner. By mid-April, over 11 million B-shares had been repurchased under this scheme, which is set to continue until early 2027. The immediate focus now shifts to the first-quarter results, which will reveal whether operational and clinical strengths can begin to offset the heavy weight of the company's own sobering annual forecast.